Aureka Biotechnologies Closes $35 Million Series A+ Funding Round

AI Pharma Sector Lands Another Major Funding Round

AI-driven antibody drug development company Aureka Biotechnologies recently announced the completion of a $35 million Series A+ funding round. The round was led by Sequoia China, with participation from Matrix Partners China and Boyuan Capital. Existing investors including 5Y Capital, Qiming Venture Partners, and Neurely Capital also increased their stakes.

Notably, Aureka Biotechnologies had just completed a Series A round of tens of millions of dollars at the end of last year. To date, the company's cumulative Series A funding has reached nearly $100 million, reflecting strong capital market confidence in the AI pharma sector — particularly in generative antibody drug design.

Use of Funds: Strengthening Platform and Infrastructure

According to Aureka Biotechnologies, the newly raised capital will be used to advance the development of its proprietary innovative functional antibody design platform, AuraIDE™. Investment will focus on three key areas: expanding foundation model and AI agent capabilities, enhancing high-throughput and high-content experimental platform facilities, and further streamlining the critical pipeline from project initiation and molecular design through to translational development.

In the three years since its founding in 2023, Aureka Biotechnologies has completed a clear progression — from building a generative antibody drug R&D platform, to integrating AI agents deeply into drug molecular design and development, and finally to scaling up these capabilities.

Founder's Perspective: Infrastructure Is Key to AI Pharma Commercialization

Aureka Biotechnologies founder and CEO Zhao Wei'an believes that the core challenge the company currently faces lies in building the "supporting infrastructure" for AI drug development systems, enabling faster validation of the real-world effectiveness of new targets and new molecules designed by AI agents. He noted that "this directly impacts the commercialization capabilities of AI-driven pharmaceutical companies."

Zhao further analyzed that the reason general-purpose large model companies are more capable is fundamentally rooted in the infrastructure they have built over time, which enables rapid validation of innovation value and generates real feedback loops. However, in the pharmaceutical industry, the cycle from molecular design to clinical validation is far longer than that of digital products, making the establishment of an efficient experimental validation closed loop the key bottleneck for AI pharma companies to overcome.

Industry Outlook: AI Antibody Drug Development Accelerates Toward Real-World Application

With its first antibody drug about to enter clinical trials, Aureka Biotechnologies is transitioning from "platform capability validation" to a new phase of "clinical value realization." Amid increasingly fierce global competition in the AI pharma sector, companies that possess a complete closed-loop capability — from AI molecular design to high-throughput experimental validation — will be more likely to pioneer a viable commercialization pathway.

In recent years, the penetration of generative AI technology in the biopharmaceutical sector has been accelerating. From target discovery to molecular design, and from lead compound optimization to preclinical evaluation, AI is reshaping every stage of traditional drug development. Aureka Biotechnologies' nearly $100 million in cumulative Series A funding sends a clear signal: capital is betting on companies that can truly translate AI capabilities into clinical pipelines.